|
Rheumatoid Arthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that among the four compounds of the TW, T-96 possesses highest anti-rheumatoid arthritis activity though inhibiting IL-1-mediated inflammatory signaling pathways.
|
31585899 |
2020 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study highlights the importance of IL-1α in mediating IL-1β-induced inflammation in addition to maintaining its expression and providing a rationale for targeting IL-1α to minimize the role of IL-1β in inflammatory diseases like RA.-Singh, A. K., Fechtner, S., Chourasia, M., Sicalo, J., Ahmed, S. Critical role of IL-1α in IL-1β-induced inflammatory responses: cooperation with NF-κBp65 in transcriptional regulation.
|
30272996 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
On this basis, we aimed at investigating whether interleukin-1 (IL-1) inhibition with anakinra, a recombinant human IL-1 receptor antagonist, could improve both glycaemic and inflammatory parameters in participants with RA and T2D compared with tumour necrosis factor (TNF) inhibitors (TNFis).
|
31513665 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-1 and IL-33 are cytokines found to be implicated in many inflammatory disorders including rheumatoid arthritis, atherosclerosis and psoriasis.
|
30574739 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The IL-1 super-family of cytokines and receptors is highly pleiotropic and plays a fundamental role in the pathogenesis of several auto-inflammatory conditions including rheumatoid arthritis, multiple sclerosis and psoriasis.
|
31231388 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this meta-analysis, 37 case-control studies comprising 23,506 RA patients and 25,984 healthy individuals were found for analyzing the IL23R, IL21, and IL1A gene polymorphism and risk of RA.
|
30924147 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SKI306X reduced Th17 cytokine-induced TNF-, IL-1, and RANKL expression and osteoclast differentiation, providing novel insights into adjuvant therapy for regulating inflammation and joint destruction in RA.
|
31295961 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Improved knowledge of the immune/inflammatory pathways, which characterise the pathophysiology of rheumatoid arthritis (RA) and seronegative spondyloarthropathies (SpA), such as ankylosing spondylitis (AS) and psoriatic arthritis (PsA), have provided the link between inflammation and bone loss, via a complex network of bone cells, T and B cells, pro-inflammatory cytokines such as TNF-α, IL1, IL6, IL17, IL23, costimulator molecules, signalling pathways including both RANKL/RANK/OPG and Wnt signallings.
|
30557124 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, it has been shown that some well-known pathogenic mediators in rheumatoid arthritis (RA), such as interleukin-1β (IL-1β) and tumor necrosis factor (TNF), could play a pathogenic role in insulin resistance and (IR) and type 2 diabetes (T2D).In this 6-month longitudinal study, we aimed at investigating if the inhibition of IL-1 or TNF is associated with an improvement of IR in RA patients with comorbid T2D and the possible effects on selected serum adipokines.
|
30762811 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that this mechanism of epidermal thickening differs from that observed in IL1-ra-treated animals.
|
29268236 |
2018 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-1 is a cytokine that exerts a pivotal role in innate immunity and in the pathogenesis of some autoimmune diseases, such as rheumatoid arthritis, and in autoinflammatory disorders, as familial Mediterranean fever and cryopyrin-associated periodic syndromes.
|
29633070 |
2018 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Over the past 30 years, IL-1-mediated inflammation has been established in a broad spectrum of diseases, ranging from rare autoinflammatory diseases to common conditions such as gout and rheumatoid arthritis (RA), type 2 diabetes, atherosclerosis, and acute myocardial infarction.
|
30459597 |
2018 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, MA could effectively stimulate the innate immune cytokines (IL-1[Formula: see text], IL-1[Formula: see text], IL-6, IL-7, IL-18, TNF-[Formula: see text]) and adaptive immunity cytokines (IL-2, IL-12, IFN-[Formula: see text], IL-4, IL-5, IL-10, IL-13, IL-17) as the main part of the immune response and repaired damage of RA.
|
30001644 |
2018 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CH65-stimulated RA PBMC produced moderate to high amounts of IL-1, TNF and IL-6.
|
24131486 |
2017 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Forty consecutive patients who experienced TdP (TdP cohort) were consecutively enrolled and circulating levels of C-reactive protein (CRP) and proinflammatory cytokines (interleukin-6 (IL-6), tumour necrosis factor alpha (TNFα), interleukin-1 (IL-1)) were compared with patients with active rheumatoid arthritis (RA), comorbidity or healthy controls.
|
28490617 |
2017 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this trial is to evaluate the contribution of low-dose sequential kinetic activation (SKA) IL-4, IL-10, and anti-IL-1 antibodies (10 fg/mL) in patients affected by RA in maintaining LDA or remission obtained after biological therapy.
|
28408798 |
2017 |
|
Rheumatoid Arthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this paper we profile cytokine secretion by primary human SFs from healthy tissues and from donors with RA and show that SF activation by TNF, IL-1α, and polyinosinic-polycytidylic acid (Poly(I:C)) cause secretion of multiple cytokines found at high levels in RA synovial fluids.
|
27820799 |
2017 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Also, we found three negative associated haplotypes with PE: IL-1α + 4845 G/IL-1β -511 A, IL-1β + 3954 C/IL-1β -511 A and interestingly IL-1α -889 C/IL-1β -511 A also with a positive association with RA.
|
28358286 |
2017 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin-1 receptor antagonist (IL-1Ra) acts as an inhibitor of IL-1; which is one of the culprit cytokines in rheumatoid arthritis (RA).
|
27105431 |
2016 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-1 targeted therapies have been successfully employed to treat a range of inflammatory conditions such as rheumatoid arthritis and gouty arthritis.
|
27001429 |
2016 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interleukin-33 (IL-33) is a member of the IL-1 family, and previous studies found the single-nucleotide polymorphisms (SNPs) in the IL-33 gene was related to susceptibility to autoimmune diseases, including rheumatoid arthritis, ankylosing spondylitis and Behcet's disease.
|
27603301 |
2016 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No association was between RA susceptibility and the IL-1A -889 C/T, IL-1A +4845 G/T, and IL-1RN +2018 C/T polymorphisms.
|
26718437 |
2015 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
According to EF, men carrying IL1-RN VNTR A1A3 (P=0.005 OR=5.28) and IL1-β-511C/C (P=0.015 OR=2.61) genotypes develop non EF of RA.
|
26003199 |
2015 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human genetic data suggest that long-term dual IL-1α/β inhibition could increase cardiovascular risk and, conversely, reduce the risk of development of rheumatoid arthritis.
|
25726324 |
2015 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anakinra (IL-1 receptor antagonist) and tocilizumab (monoclonal IL-6 receptor antibody) are two known anti-inflammatory agents successfully used in the treatment of inflammatory states like rheumatoid arthritis.
|
23635711 |
2014 |